| | | |

Bonefos: Ready to Fight Metastatic Bone Disease

Metastatic Bone Disease (MBD) is an illness that can have a lot of complications. Fortunately, bone resorption treatment has drastically changed in the last 30 years when bisphosphonates evolved as a drug that could help heal bone diseases. Bonefos is a bisphosphonate that was launched in 1985 in Finland. Now this drug is available in more than 60 countries.

Bonefos includes clodronate (disodium clodronate). This drug is available in oral and intravenous formulations giving patients extra flexibility in their treatment regimens. This bisphosphonate is used to control increased states of bone resorption.

In contrast to other bisphosphonates, Bonefos can not be responsible of severe adverse gastrointestinal reactions. Oral Bonefos has the advantage of being able to be used in high doses (a maximum of 3200 mg per day) to treat osteolysis and as a therapy for a long term. Several clinical trials that involved thousands of patients have proven the efficiency and tolerability that Bonefos has.

As mentioned above, Bonefos can be administered orally and intravenously. The oral formulation of Bonefos has tablets of 800 mg of disodium clodronate and capsules of 400 mg of disodium clodronate available. The intravenous infusion of Bonefos contains a concentrate of 60 mg/ml of disodium clodronate.

Is important to consider that sufficient fluid intake is needed while using Bonefos and that it must be used carefully in patients that have renal failure. This because most of the time, clodronate is eliminated through the kidneys.

View more Free Content by rxboomer at GetYourContent.com

Visit RxBoomer.com for information about various Prescription Drugs and/or Drug Companies.

| | | |

If you have any problems, suggestions, or comments please E-mail or call Joe at 1-877-792-3866 ext. 108

2/7/2012 6:03:13 PM